What is economic value, and who creates it? | Mariana Mazzucato

Summary

Mariana Mazzucato argues that how economies define and measure “value” has drifted toward value extraction (profits/rents derived from existing advantages or financialization) rather than value creation (productive activity that expands the economy’s future productive capacity). She traces this shift in economic theory and shows how it affects GDP accounting, corporate reinvestment, innovation incentives, and even pricing in sectors like pharmaceuticals.

---

Core thesis: value ≠ price, and value creation ≠ value extraction

Modern practice often treats anything priced (or earning high market value) as “value,” creating a tautology:

• If a firm/worker earns more, that pricing is taken as proof they “created value,” but the measurement is driven by prices that already assume value.

A better framework distinguishes:

• Productive vs unproductive activities
• Reinvestment vs siphoning-out
• Friction/market imperfections vs rents/unearned income
• Long-term innovation vs short-term financial engineering

---

How economic thinking shifted (and why it matters for business strategy)

Mazzucato describes two historical “logics”:

Pre-neoclassical focus: objective conditions + reproduction capacity (value creation lens)

Physiocrats (e.g., François Quesnay / Tableau Économique):

• Value is tied to productive labor/activities (initially farm labor).
• Central concern: whether produced value is reinvested back to maintain/expand productive capacity.
• Uses scenario simulation (“big data”/spreadsheet metaphor) to model how siphoning value harms future production.

Neoclassical shift: subjective decisions + price as the output of exchange

• Workers optimize leisure vs work; consumers optimize utility; firms optimize profits.
• Aggregated market outcomes yield equilibrium.
• Prices then “reveal value,” reversing causality:
  • Instead of asking “what creates value?”, the question becomes “what does the price system reveal?”

Business impact (execution-level)

Steering and remuneration increasingly follow:

• market prices and share prices
• financial metrics that can reward extraction even when productive reinvestment falls

And GDP/output measures become distorted when they capture only priced activities.

---

Concrete accounting and sector examples: where measurement fails

GDP accounting: priced activity ≠ productive value

Examples:

• If you marry your babysitter, GDP falls (unpaid household care was already happening).
• If you pollute, GDP can rise (clean-up becomes a priced activity).

Finance inclusion changed:

• Before ~1970, much of finance wasn’t included in GDP as “production.”
• Later, net interest payments were added via labels:
  • “financial intermediation” and “risk-taking”
• Result: a growing share of finance effectively became finance financing itself.

Implication for operators: systems that reward “priced outcomes” can incentivize business models that grow “economic value on paper” without equivalent growth in real productive capacity.

---

Financialization & reinvestment: the operational problem

Mazzucato links measurement to corporate behavior:

Share buybacks as value extraction (not productive reinvestment)

She argues profit distribution shifted toward:

• share buybacks → stock options → executive pay
• rather than reinvestment into:
  • training (human capital)
  • R&D
  • production expansion

Metrics cited:

• Over the last 10 years, 466 of S&P 500 companies spent over $4 trillion on share buybacks.

Macro KPI implication

• Aggregate business investment (as % of GDP) shows a declining trend relative to prior periods, consistent with reinvestment shortfalls.

Downstream impacts:

• weaker skills development and job creation
• increased economic risk if productivity growth depends on reinvestment

---

Pricing power in pharma: profits/rents disguised as “value”

A pharmaceutical example illustrates price-as-value thinking:

• When an antibiotic price rises 400% overnight, the CEO defends it as:
  • “moral imperative to allow prices to go what the market will bear”

Counterpoint:

• The US NIH spends over $30B/year on medical research that enables those drugs.

Takeaway for strategy/leadership: if pricing is treated as the sole measure of value, organizations may justify high-margin extraction even when substantial value creation is funded elsewhere (public R&D) or when the outcome constrains access.

---

Frameworks/playbooks implied by the talk (business relevance)

• Value creation vs value extraction diagnostic

  • Assess whether profit is primarily used for:
    • reinvestment (R&D, capex, training, scaling production), or
    • siphoning (buybacks, rent capture, financial self-referential activity)

• “Production boundary” steering

  • Rebalance what activities are supported/allowed to grow based on productive contribution vs rent-seeking.

• Measurement redesign

  • Don’t only track “priced output” (GDP-style); incorporate indicators of:
    • well-being/productive capacity
    • reinvestment rates and long-term capability building

• Incentives toward long-termism (finance reform lens)

  • Reward:
    • patient capital
    • long-duration investment
    • less short-term financial pressure

---

Actionable recommendations mentioned (institutional, with operator analogs)

• Reform finance to reduce short-termism Example proposed but not adopted globally after the crisis:

  • a financial transaction tax (to shift incentives toward long-term behavior)

• Create/expand public financial institutions Provide long-term committed finance for:

  • small firm growth
  • infrastructure
  • innovation

• Reframe evaluation beyond cost-benefit / NPV alone Some initiatives (e.g., the Moon landing) may not start if assessed only by narrow financial criteria. Value creation can include:

  • learning
  • spillovers
  • capability building

• Nurture experimentation Use procurement and institutional mechanisms to fund “bottom-up solutions,” treating failures as learning. Example: Bell Labs (linked to AT&T history) required reinvestment to sustain monopoly conditions, supporting R&D beyond telecom.

---

High-level business execution themes to carry forward

• If you only optimize share price or priced transactions, you may drift into extraction.
• Track reinvestment into productive capacity (skills, R&D, innovation pipeline) as a primary KPI—not only financial outcomes.
• Redesign performance measurement so success correlates with real value creation rather than price-driven valuation.

---

Mentioned presenters/sources

• Presenter: Mariana Mazzucato
• Historical sources/figures referenced: François Quesnay, Adam Smith, David Ricardo, Karl Marx
• Institutions/data referenced:
  • Goldman Sachs (CEO quote cited)
  • US taxpayer bailouts
  • United Nations System of National Accounts (SNA)
  • Bank of England data (for finance growth)
  • National Institutes of Health (NIH)
  • S&P 500 (buyback data)
  • AT&T / Bell Labs
• Programs/policies mentioned:
  • financial transaction tax (as an idea)
  • New Zealand gross national happiness indicator
  • Bhutan well-being indicators
  • NASA/Moon landing (public-private investment example)